The rapid development of resistance to BRAF/MEK inhibitors and their dynamic impacts on the tumor microenvironment and systemic antitumor immunity should also be considered to determine the sequencing and scheduling of the combination. This evidence concerns the gene MAP2K7 and neoplasm.